Revolutionizing Cardiac
Surgery Outcomes
At BioXgen, we are pioneering a future where post-surgical atrial fibrillation (AFib)—a common and potentially life-threatening complication—no longer stands in the way of recovery. Our mission is to revolutionize cardiac care by drastically reducing AFib risks after surgery, safeguarding patients from devastating complications like stroke, heart arrhythmias, and prolonged recovery times empowering patients with faster healing, fewer hospital readmissions, and restored quality of life.
BioXgen’s mission is to drastically reduce post-surgical AFib complications while improving patient outcomes, lowering costs, and saving lives.
BioXgen is a trailblazing biologics company revolutionizing cardiac care with its proprietary extracellular matrix (ECM) technology. Applied to the epicardium, our innovative solution prevents postoperative atrial fibrillation while promoting myocardial cell regeneration and heart remodeling.
Reducing post-surgery AFib from 30-50% to less than 8%, drastically improving patient recovery.
Faster healing means patients return home sooner — cutting costs and improving overall outcomes.
Pioneering biologics that transform heart surgery and set a new standard for cardiovascular care.
